Related Experiment Video
Updated: Apr 28, 2026

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
Phage Display Reveals VLRB-Mediated Recognition of Minimal Tumor Glycan Antigen Sialyl-Tn
Mark Rickard N Angelia1,2, Abigail Joy D Rodelas-Angelia1, Youngrim Kim1
1Laboratory of Aquatic Animal Diseases, Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University, 501, Jinju-Daero, Jinju-si 52828, Republic of Korea.
Abstract:
Sialyl-Tn (sTn) is a tumor-associated carbohydrate antigen (TACA) abundantly expressed by various types of carcinomas. While conventional antibody-based platforms have traditionally been used for the detection and targeting of sTn, alternative binding scaffolds may offer distinct advantages. Variable lymphocyte receptor B (VLRB), the immunoglobulin-like molecule of jawless vertebrates, offers a promising alternative for glycan recognition. In this study, a phage-displayed VLRB library was utilized to identify sTn-specific binders. Two candidates, designated as ccombodies A8 and B11, were isolated after four rounds of biopanning. Both were expressed and purified using Ni-affinity and FPLC, yielding proteins with apparent molecular weights of ~27 kDa in SDS-PAGE. Sequence analysis revealed a preference for glycan-binding residues in randomized hypervariable regions, with A8 exhibiting an increased aliphatic content. ELISA confirmed selective binding to sTn and other O-glycans containing the core α-GalNAc, with EC50 values of 18.2 and 14.2 nM for A8 and B11, respectively. Vicia villosa lectin inhibited ccombody binding to sTn, indicating shared epitope recognition. Additionally, both ccombodies bound to sTn-positive glycoproteins and carcinoma cell lines HeLa and LS174T. These findings demonstrate that phage display of VLRBs enables the identification of high-affinity, glycan-specific binders, offering a compelling alternative to immunoglobulin-based platforms for future diagnostic and therapeutic applications targeting tumor-associated glycans.
Insights
Variable lymphocyte receptor B (VLRB) ccombodies were developed to detect Sialyl-Tn (sTn), a tumor antigen. These VLRBs show high affinity and specificity for sTn, offering a new tool for cancer diagnostics and therapeutics.
Area of Science:
- Biochemistry
- Immunology
- Glycobiology
Background:
- Sialyl-Tn (sTn) is a tumor-associated carbohydrate antigen (TACA) found in many carcinomas.
- Conventional antibody platforms for sTn detection have limitations.
- Variable lymphocyte receptor B (VLRB) from jawless vertebrates presents an alternative scaffold for glycan recognition.
Purpose of the Study:
- To identify and characterize novel sTn-specific binding molecules using VLRBs.
- To evaluate VLRB-based binders as alternatives to antibodies for targeting tumor-associated glycans.
Main Methods:
- Construction and screening of a phage-displayed VLRB library against sTn.
- Isolation and purification of VLRB candidates (ccombodies A8 and B11).
- Biochemical characterization using SDS-PAGE, ELISA, and inhibition assays with Vicia villosa lectin.
Main Results:
- Two high-affinity VLRB binders, A8 and B11, were identified with nanomolar EC50 values for sTn.
- VLRB binders demonstrated specificity for sTn and other core α-GalNAc-containing O-glycans.
- ccombodies bound to sTn-positive glycoproteins and carcinoma cell lines (HeLa, LS174T).
Conclusions:
- Phage display of VLRBs is effective for generating high-affinity, glycan-specific binders.
- VLRB-based ccombodies offer a promising alternative to antibodies for targeting tumor-associated glycans.
- These findings support the development of VLRB scaffolds for cancer diagnostics and therapeutics.
More Related Videos
08:09Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
07:32Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019